CTOs on the Move

Revance

www.revance.com

 
Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.revance.com
  • 7555 Gateway Boulevard
    Newark, CA USA 94560
  • Phone: 510.742.3400

Executives

Name Title Contact Details
Nick Crowe
Chief Operating Officer Profile
Michelle Wong
Chief Operating Officer Profile

Similar Companies

Aegerion

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases.

ONL Therapeutics

ONL Therapeutics (ONL) is a clinical-stage biopharmaceutical company committed to protecting and improving the vision of patients with a range of retinal disease and conditions.​

Bio-Green Planet

Bio-Green Planet is a Scottsdale, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Capital Genomix (US Headquarters)

Capital Genomix (US Headquarters) is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

480 Biomedical

480 Biomedical focuses on the development of a bioresorbable scaffold for treating occlusive disease in the superficial femoral artery.